Mojia Biotech, a Shanghai-based leading bio-manufacturing company dedicated to sustainable development and carbon neutrality, announced the completion of an $80 million Series B Financing. Temasek led the round, with participation from LYZZ Capital, Sento Investment, existing investors Bits x Bites and Asia Green Fund, and other investors. The funds will be used to commercialize its Viridimin^TM brand of animal-feed additives, scale up manufacturing capacity for Aliphane^TM series of bio-based materials, advance its product pipeline and expand its global R&D capabilities. 

For over a century, the petrochemical industry has created an abundant chemical universe for daily life and industrial applications.   While significantly enhancing our living conditions, the petroleum-based manufacturing processes have also caused tremendous environmental and social challenges, such as greenhouse gas emissions and environmental pollutions. To promote sustainable development, the world is under pressing needs to embrace a much greener and safer supply of chemical and materials, either by feed-stock switch toward renewable carbon sources, or by manufacturing process redesign incorporating the latest advances in synthetic biology.

With its proprietary platform for enzyme and metabolic engineering, Mojia Biotech is committed to transforming the chemical and polymer space.  In the past few years, Mojia Biotech has developed innovative pathways to produce Viridimin^TM brand of Vitamin B5.   Compared to the prevailing approaches, Mojia’s patented bio-process not only consumes less energy and emits less wastes, but also ensures a more stable supply of Vitamin B5 because of frequent production disruptions caused by tightening environmental regulations in China.  Mojia is planning to bring this state-of-art facility into commission in June 2022.The second product that Mojia Biotech aims to bring to the market is Aliphane^TM series of biopolymer products, which is extremely versatile and has great potential in coating and adhesive applications. 

Ansen Chiew, co-founder of Mojia Biotech, says: “Over the last decade, we have established a comprehensive R&D platform combining biology, chemistry, engineering and polymer sciences,
accumulated hands-on experiences in large-scale bio-production and built strong global commercialization capabilities. Our green technology is a prove that it is possible to address environmental pollution associated with traditional chemical industry yet achieving cost advantage and performance supercity.  We greatly appreciate visionary and like-minded investors like Temasek, Asia Green Fund, Bits x Bites and LYZZ Capital in supporting our mission for sustainable development and carbon neutrality.”

Joseph Zhou, managing partner of Bits x Bites, says: “Sustainable ingredient manufacturing is a pillar  for a thriving green economy. And with the recent delays and shortages in the global supply chain highlighting the importance to reduce reliance on raw material imports, we see huge potential for Mojia Biotech to apply its technology across different chemical ingredients , and to become a leader for next-generation green chemical production. ”

Bo Bai, Chairman and Founder of Asia Green Fund, says: “Chemical bio-manufacturing is one of today’s most dynamic fields in the chemical industry. With its R&D activities and cross-disciplinary innovations, Mojia Biotech has effectively tackled issues such as long processes, high energy consumption and environmentally polluting by-products. We are pleased to work with Mojia Biotech to promote green and cost-leading innovation in chemicals and new materials.”